Related references
Note: Only part of the references are listed.Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidances from Regulatory Agencies: Focus on CYP3A4 mRNA In Vitro Response Thresholds, Variability, and Clinical Relevance
Jane R. Kenny et al.
DRUG METABOLISM AND DISPOSITION (2018)
In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation
Jennifer E. Sager et al.
BIOCHEMICAL PHARMACOLOGY (2017)
Contribution of Metabolites to P450 Inhibition-Based Drug-Drug Interactions: Scholarship from the Drug Metabolism Leadership Group of the Innovation and Quality Consortium Metabolite Group
Hongbin Yu et al.
DRUG METABOLISM AND DISPOSITION (2015)
Evaluation of Various Static In Vitro-In Vivo Extrapolation Models for Risk Assessment of the CYP3A Inhibition Potential of an Investigational Drug
Md L. T. Vieiral et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Hospital admissions/visits associated with drug-drug interactions: a systematic review and meta-analysis
Supinya Dechanont et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2014)
A Perspective on the Contribution of Metabolites to Drug-Drug Interaction Potential: The Need to Consider Both Circulating Levels and Inhibition Potency
Hongbin Yu et al.
DRUG METABOLISM AND DISPOSITION (2013)
Drug Metabolites as Cytochrome P450 Inhibitors: A Retrospective Analysis and Proposed Algorithm for Evaluation of the Pharmacokinetic Interaction Potential of Metabolites in Drug Discovery and Development
Ernesto Callegari et al.
DRUG METABOLISM AND DISPOSITION (2013)
In vitro-to-in vivo predictions of drug-drug interactions involving multiple reversible inhibitors
Justin D. Lutz et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2012)
Are Circulating Metabolites Important in Drug-Drug Interactions?: Quantitative Analysis of Risk Prediction and Inhibitory Potency
C. K. Yeung et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review
P. Zhao et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Evaluation of models for predicting drug-drug interactions due to induction
Odette A. Fahmi et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2010)
Qualitative Analysis of the Role of Metabolites in Inhibitory Drug-Drug Interactions: Literature Evaluation Based on the Metabolism and Transport Drug Interaction Database
Nina Isoherranen et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2009)
An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction
Melinda J. Reese et al.
DRUG METABOLISM AND DISPOSITION (2008)
Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo
I. E. Templeton et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Prediction of in vivo drug-drug interactions from in vitro data:: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant
HS Brown et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations
JW Jefferson et al.
CLINICAL THERAPEUTICS (2005)
Role of itraconazole metabolites in CYP3A4 inhibition
N Isoherranen et al.
DRUG METABOLISM AND DISPOSITION (2004)
Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers
AT Harvey et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2001)
Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: Prediction of in vivo drug interactions
K Ohyama et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2000)
Share Paper
